Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

NCT07062627 | Recruiting Phase 2 DMC

• 1 other identifier: Anbal-Cel
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical study aims to evaluate the tolerability, safety, and efficacy of Anbal-cel in patients with recurrent or refractory PCNSL or SCNSL. Subjects who have provided written consent and meet the inclusion and exclusion criteria through screening evaluations will undergo leukapheresis (LP) for Anbal-cel manufacturing. Subjects whose collected nucleated cells are confirmed suitable for Anbal-cel production will be enrolled in the clinical study. Prior to Anbal-cel administration, lymphodepletion therapy will be performed and must be completed at least 2 days before Anbal-cel administration. Anbal-cel will be administered to subjects who meet the inclusion and exclusion criteria for Anbal-cel administration. Study subjects will be hospitalized for a minimum of 7 days to closely monitor adverse events and receive prompt necessary treatment after Anbal-cel administration. All study subjects will undergo primary visit evaluations for 12 months following Anbal-cel administration. Subjects who discontinue primary visit evaluations before the 12-month visit will undergo an end of study 1 (EOS1) visit for safety observation. For subjects whose primary visit evaluations end before the 12-month visit due to disease progression (PD), withdrawal of consent for primary visit evaluations, or subsequent anti-cancer therapy, secondary follow-up visits will be conducted from the EOS1 visit to the 12-month time point (EOS2). The timing of the first secondary follow-up visit will be determined based on when the subject's primary visit evaluation was discontinued. A separate long-term follow-up study is planned to monitor long-term safety, including delayed adverse events (AEs), in subjects who received Anbal-cel. In this long-term follow-up study, each subject will be followed for 15 years from the date of Anbal-cel administration. All specific details, including the visit schedule and examination items for the long-term follow-up study, will be described in a separate protocol.

Conditions

Diffuse Large B Cell Lymphoma (DLBCL); Primary CNS Lymphoma (PCNSL)

Keywords

lymphoma; CAR-T; Anbalcabtagene autoleucel

Outcome Measures

Primary Outcomes (1)

• The overall response rate (ORR) of Anbal-cel, as determined according to the International Primary CNS Lymphoma Collaborative Group.

  The objective response rate (ORR) is defined as the proportion of subjects who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), as assessed by the investigator. Subjects who do not achieve CR or PR will be considered non-responders in the analysis.

  24 months

Secondary Outcomes (8)

• Complete response rate (CRR)

  24 months

• time to response, TTR

  24 months

• Duration of response (DOR)

  24 months

• Event-free survival (EFS)

  24 months

• Progression-free survival (PFS)

  24 months

Study Arms (1)

Anbal-Cel arm

EXPERIMENTAL

Anbal-cel will be administered as a single intravenous infusion on Day 1, within 30 minutes of thawing. The intended dose is 2 × 10⁶ CAR-T cells/kg, with a maximum of 2 × 10⁸ cells.

Genetic: Anbal-cel

Interventions

Anbal-cel GENETIC

On Day 1 (D1), Anbal-cel will be administered only to subjects who meet the final inclusion/exclusion criteria for Anbal-cel administration before the infusion. As premedication before Anbal-cel administration, acetaminophen or paracetamol, and diphenhydramine or H1 antihistamine will be given. Anbal-cel will be administered as a single intravenous infusion on Day 1 within 30 minutes of thawing, at the dose presented in the following table: Dose: 2x10\^6 (CAR-T cells/kg)\* Maximum 2 x 10\^8 cells

Anbal-Cel arm

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Individuals aged 19 years or older who voluntarily agree to participate in this clinical study and provide written consent.
• Patients with recurrent/refractory B-cell lymphoma confirmed histologically according to the 2017 WHO classification, and who meet one of the following conditions:
• Primary central nervous system lymphoma (PCNSL) of the DLBCL subtype Secondary central nervous system involvement of DLBCL with no involvement outside the central nervous system
• Patients who failed treatment with a previous regimen that included high-dose methotrexate or patients intolerant to high-dose methotrexate.
• Patients who agree to provide tumor tissue. If a stored tumor tissue sample is available, it can be submitted only if it was collected within 6 months prior to participation in the clinical study and if no systemic anticancer treatment was administered after collection. If the stored tissue sample does not meet these conditions, tumor tissue must be obtained through a core needle biopsy or excisional biopsy during the screening period. If the investigator deems the biopsy to be medically unsafe for the patient, the decision on whether to enroll the patient in the clinical study can be made in consultation with the patient's clinical physician.
• Individuals with an ECOG performance status score of 2 or lower at the time of screening.
• Individuals with appropriate renal and liver function confirmed by laboratory test results:
• Total Bilirubin ≤2.0 mg/dL (for individuals with Gilbert-Meulengracht syndrome: total bilirubin ≤3.0 × upper limit of normal (ULN), direct bilirubin ≤1.5 x ULN) Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 × ULN (if liver metastasis is confirmed: AST, ALT ≤5 × ULN) Serum creatinine ≤1.5 x ULN Estimated glomerular filtration rate (eGFR)\* ≥60 mL/min/1.73 m²
• \*MDRD-GFR (mL/min/1.73 m²) = 186 × (serum creatinine)-1.154 × (age)-0.203 (× 0.742 for females)
• Individuals with appropriate hematologic function confirmed within 2 weeks prior to screening without transfusion, based on the following criteria:
• Hemoglobin \>8.0 g/dL Absolute neutrophil count (ANC) \>1,000/μL Absolute lymphocyte count (ALC) ≥300/μL Platelets ≥50,000/μL
• Individuals who are hemodynamically stable at the time of screening, have no signs of pericardial effusion, and have a left ventricular ejection fraction of 50% or higher based on an echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
• Individuals from whom adequate non-mobilized cells for Anbal-cel manufacturing can be collected through leukapheresis.
• Individuals with an expected survival of 12 weeks or longer.
• Individuals who agree to comply with the scheduled site visits, examination schedules, and assessments as per the protocol during the course of the clinical study, including primary and secondary follow-up visits.

You may not qualify if:

• Individuals with a history of allogeneic hematopoietic stem cell transplantation.
• Individuals with the following medical history:
• History of other malignancies, except B-cell non-Hodgkin lymphoma, within 3 years prior to screening (however, individuals with a history of basal cell carcinoma, squamous cell carcinoma of the skin, localized prostate cancer, papillary thyroid cancer, cervical carcinoma in situ, or early-stage gastric cancer may participate if the investigator considers them to be fully cured after successful treatment, even if 3 years have not passed).
• History of unstable angina and/or myocardial infarction within 12 months prior to screening.
• History of thromboembolism, pulmonary embolism, or bleeding diatheses within 6 months prior to screening.
• History of hypoxia, clinically significant pleural effusion, or abnormal electrocardiogram findings within 6 months prior to screening.
• Individuals with the following conditions at the time of screening:
• Known positive for human immunodeficiency virus (HIV).
• Active neurological autoimmune or inflammatory diseases (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).
• Recurrent or symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response despite treatment in the 3 months prior to screening.
• Individuals whose disease is rapidly progressing, as determined by the investigator.
• Individuals who have undergone major surgery requiring general anesthesia or respiratory support within 4 weeks prior to screening (however, video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery is permissible if conducted within 2 weeks).
• Individuals with severe infections requiring the administration of antibiotics, antifungals, or antivirals at the time of screening or with uncontrolled active infections.
• Individuals who have received or been exposed to other investigational drugs or devices within 4 weeks prior to screening.
• Pregnant or breastfeeding women.

Sponsors & Collaborators

• Hyungwoo Cho: lead
• Asan Medical Center: collaborator

Study Sites (1)

Asan Medical Center

Seoul, 05505, South Korea

RECRUITING

MeSH Terms

Conditions

Lymphoma, Large B-Cell, Diffuse; Lymphoma

Condition Hierarchy (Ancestors)

Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Hyungwoo Cho, Ph.D

  Asan Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hyungwoo Cho, Ph.D

CONTACT

82-2-3010-3205; hwcho268@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: May 27, 2025
• First Posted: July 14, 2025
• Study Start: November 12, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: December 17, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)